score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3945	436.0	1.6e-05	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0	0.0	0.0	0.0	BRAF p.V600E (Missense)	1.0	MEL-IPI_Pat37	MEL-IPI_Pat37-Tumor-SM-53U3Y	MEL-IPI_Pat37-Normal-SM-4NFV4
Putatively Actionable			Guideline	Copy Number	RB1	Deletion				0.0	0.0																Putatively Actionable	0.0	Deletion of chromosome 13 seems to have an amplifying effect on cell cycle gene expression and is reported to be associated with short event-free survival (EFS) and overall survival (OS). This copy loss event results in haploinsufficiency of RB1 and other genes mapped to chromosome 13.	National Comprehensive Cancer Network. Multiple Myeloma NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf	0				RB1 Deletion		MEL-IPI_Pat37	MEL-IPI_Pat37-Tumor-SM-53U3Y	
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.G182E	0.2308	182.0	8e-06	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0.0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1	0	117.0	0.2308	1.0	JAK1 p.G182E (Missense)		MEL-IPI_Pat37	MEL-IPI_Pat37-Tumor-SM-53U3Y	MEL-IPI_Pat37-Normal-SM-4NFV4
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.G667S	0.0163	492.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881													0	78.0	0.0	0.0679	MET p.G667S (Missense)	0.0	MEL-IPI_Pat37	MEL-IPI_Pat37-Tumor-SM-53U3Y	MEL-IPI_Pat37-Normal-SM-4NFV4
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.S215R	0.8142	113.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0.0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	212.0	0.9717	1.0	TP53 p.S215R (Missense)		MEL-IPI_Pat37	MEL-IPI_Pat37-Tumor-SM-53U3Y	MEL-IPI_Pat37-Normal-SM-4NFV4
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						MEL-IPI_Pat37		
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.S660N	0.4647	241.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951													0	0.0	0.0	0.0	PBRM1 p.S660N (Missense)		MEL-IPI_Pat37	MEL-IPI_Pat37-Tumor-SM-53U3Y	MEL-IPI_Pat37-Normal-SM-4NFV4
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Splice Site		0.0654	107.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0.0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744	0	0.0	0.0	0.0	ARID1A  (Splice Site)		MEL-IPI_Pat37	MEL-IPI_Pat37-Tumor-SM-53U3Y	MEL-IPI_Pat37-Normal-SM-4NFV4
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.N553S	0.2281	342.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p													0	132.0	0.3106	1.0	PIK3CB p.N553S (Missense)	0.0	MEL-IPI_Pat37	MEL-IPI_Pat37-Tumor-SM-53U3Y	MEL-IPI_Pat37-Normal-SM-4NFV4
Biologically Relevant				Rearrangement	LIMK2	Fusion	LIMK2--HCCS			0.0	0.0																					0				LIMK2--HCCS Fusion		MEL-IPI_Pat37		
Biologically Relevant				Copy Number	RET	Amplification				0.0	0.0																					0				RET Amplification		MEL-IPI_Pat37	MEL-IPI_Pat37-Tumor-SM-53U3Y	
Biologically Relevant				Copy Number	TMPRSS2	Amplification				0.0	0.0																					0				TMPRSS2 Amplification		MEL-IPI_Pat37	MEL-IPI_Pat37-Tumor-SM-53U3Y	
Biologically Relevant				Copy Number	PMS2	Amplification				0.0	0.0																					0				PMS2 Amplification		MEL-IPI_Pat37	MEL-IPI_Pat37-Tumor-SM-53U3Y	
Biologically Relevant				Microsatellite Stability	Supporting variants		PMS2 Amplification, PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)																									0				Supporting variants: PMS2 Amplification, PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)		MEL-IPI_Pat37		
Biologically Relevant				Mutational Signature	COSMIC Signature 1	version 2	0.503																									0				COSMIC Signature (version 2) 1 (50%)		MEL-IPI_Pat37		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.432																									0				COSMIC Signature (version 2) 7 (43%)		MEL-IPI_Pat37		
